Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women

BACKGROUND: Daily oral TDF/FTC is protective against HIV infection when used for pre-exposure prophylaxis (PrEP). However, daily adherence to oral PrEP is difficult for many; therefore, finding alternative PrEP strategies remains a priority. HPTN 076 evaluated the long-acting injectable form of rilp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EClinicalMedicine
Glavni autori: Bekker, L.G., Li, S., Pathak, S., Tolley, E.E., Marzinke, M.A., Justman, J.E., Mgodi, N.M., Chirenje, M., Swaminathan, S., Adeyeye, A., Farrior, J., Hendrix, C.W., Piwowar-Manning, E., Richardson, P., Eshelman, S.H., Redinger, H., Williams, P., Sista, N.D.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Research paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139112/
https://ncbi.nlm.nih.gov/pubmed/32280940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100303
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items